Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07084948 · ClinicalTrials.gov registry record · Phase 4
Inhibition of HBV Replication and Biological Reversal of Cirrhosis (F3-F4) and HCC by Flavonoids
A Phase 4 study, sponsored by Trieu, Nguyen Thi, M.D..
- Completed
- Registry status
- Phase 4
- Development phase
- 134
- Enrollment target
NCT07084948 is a Phase 4 study that has completed, run by Trieu, Nguyen Thi, M.D.. The registered enrollment target is 134 participants.
The verdict
NCT07084948, a Phase 4 study, has completed, sponsored by Trieu, Nguyen Thi, M.D..
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 134 participants
- Enrollment target
Study Summary
SB Flavonoids for Advanced Liver Disease ManagementSB Flavonoids represents a multi-target therapeutic composition engineered for the comprehensive management of Hepatitis (Acute and Chronic), Advanced Cirrhosis (F3)-(F4), and Early-stage Hepatocellular Carcinoma (HCC).The formulation features a synergistic complex of Ascorbic Acid, L-Arginine Hydrochloride, and a high-potency flavonoid blend, including Kaempferol, Urinariaflavone, Quercetin, Rutin, and 5,6-dihydroxy-7,8,4'-trimethoxy-flavone. This combination exerts a powerful hepatoprotective and antifibrotic effect by: Structural Regeneration: Promoting the repair and regeneration of functional liver parenchyma while stabilizing hepatocyte membranes to mitigate oxidative stress. Bioreversal of Fibrosis: Actively inhibiting the activation of pro-fibrogenic cells (hepatic stellate cells) and remodeling the extracellular matrix to reverse advanced (F3)-(F4) fibrosis. Oncogenic Suppression: Inhibiting the proliferation of malignant cells to prevent the progression of early-stage liver cancer. Homeostatic Restoration: Providing essential molecular precursors to strengthen the host's immune surveillance, reduce chronic inflammation, and restore the liver's physiological and biochemical homeostasis.By addressing both viral-induced damage and structural degradation, SB Flavonoids offers a novel pathway for restoring hepatic function and systemic health in patients with progressive liver diseases.
Interventions
- DRUG Tenofovir
- DRUG Flavonoid
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 134 participants |
| Start Date | 2015-11-30 |
| Est. Completion | 2026-04-20 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07084948
The ClinicalTrials.gov registry entry for NCT07084948 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 134 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Trieu, Nguyen Thi, M.D., which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Tenofovir is the first listed.
NCT07084948 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07084948 about?
NCT07084948 is a clinical study titled "Inhibition of HBV Replication and Biological Reversal of Cirrhosis (F3-F4) and HCC by Flavonoids". SB Flavonoids for Advanced Liver Disease ManagementSB Flavonoids represents a multi-target therapeutic composition engineered for the comprehensive management of Hepatitis (Acute and Chronic), Advanced Cirrhosis (F3)-(F4), and Early-stage Hepatocellular Carcinoma (HCC).The formulation features a syn...
What is the current status of trial NCT07084948?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 134 participants. The study started on 2015-11-30. Estimated completion is 2026-04-20.
What interventions are being tested in trial NCT07084948?
The interventions under investigation include: Tenofovir (DRUG), Flavonoid (DRUG).
Who is sponsoring clinical trial NCT07084948?
This trial is sponsored by Trieu, Nguyen Thi, M.D., which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.